Autolus Therapeutics (AUTL) to Release Quarterly Earnings on Tuesday

Key Points

• Autolus Therapeutics is set to announce its Q2 2025 earnings on August 12, expecting a loss of ($0.23) per share and revenue of $12.92 million.
• The stock price has seen a 1.4% decline recently, opening at $2.35, with a market cap of $624.36 million and PE ratio of -2.76.
• Analysts have set a buy rating for the stock, with Needham & Company assigning a price target of $10.00, while the average target price stands at $9.32.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Autolus Therapeutics to post earnings of ($0.23) per share and revenue of $12.92 million for the quarter.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Trading Down 0.9%

AUTL stock traded down $0.02 during trading on Friday, reaching $2.33. 1,320,911 shares of the stock were exchanged, compared to its average volume of 1,613,352. The firm's 50 day moving average is $2.33 and its 200 day moving average is $1.90. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00. The firm has a market cap of $620.11 million, a P/E ratio of -2.65 and a beta of 1.90.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors have recently modified their holdings of AUTL. Invesco Ltd. grew its holdings in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after purchasing an additional 11,381 shares during the period. Jane Street Group LLC raised its position in shares of Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock worth $159,000 after buying an additional 91,222 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Autolus Therapeutics by 90.5% in the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company's stock worth $375,000 after buying an additional 78,058 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, July 21st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.